Clinical Trials Browser

Phase 1 × Leukemia × tislelizumab × Clear all

NCT02795182 2022-07-01

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Phase 1 Completed

75 enrolled 17 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence